Imagine a vaccine tailored to your body that could train your immune system to destroy cancer. This is the promise of personalised cancer vaccines, a revolutionary frontier in medicine. So why is this breakthrough technology still in the lab?
A 'Wanted Poster' for Your Tumour
Personalised
cancer vaccines represent a seismic shift from one-size-fits-all treatments. Unlike a flu shot that prevents illness, these are therapeutic treatments for people who already have cancer. The process begins by taking a sample of a patient's tumour and sequencing its genetics to find unique mutations, known as neoantigens. These neoantigens act like a specific fingerprint for the cancer cells. Using the same mRNA technology that powered COVID-19 vaccines, a custom vaccine is created that teaches the patient's immune system to recognise these specific neoantigens as foreign invaders. The goal is to create a highly targeted immune response that attacks only the cancer cells, sparing healthy tissue from the collateral damage often caused by chemotherapy. This turns the body’s own defence mechanisms into a precise, cancer-fighting weapon.
The Global Race and India's New Player
The quest for an approved personalised cancer vaccine is a global one, with several major players making significant strides. The most prominent is the collaboration between Moderna and Merck, whose vaccine candidate, when paired with the immunotherapy drug Keytruda, has shown it can reduce the risk of recurrence or death in high-risk melanoma patients by 42% in a large Phase 3 trial. BioNTech, another pioneer in mRNA technology, is also developing its own personalised vaccines, with promising early results in pancreatic cancer but setbacks in a trial for colorectal cancer. In India, Hyderabad-based PopVax has recently entered the field, launching its 'RNA Foundry' in late October 2026. Backed by prominent investors, PopVax aims to use AI to design and manufacture over 100 patient-specific vaccines in the next year. However, the company's work is still in its nascent stages; its vaccine candidates have not yet been administered to patients, and it plans to begin with compassionate-use pathways outside of India while preparing for the rigorous clinical trials required for full approval.
The Mountain of Challenges
The road from a promising concept to an approved treatment is incredibly long and filled with obstacles. One of the biggest hurdles is manufacturing. Creating a unique, 'n-of-1' vaccine for every single patient is a complex and resource-intensive process that flips conventional, large-batch manufacturing on its head. The timeline, from taking a tumour biopsy to delivering the final vaccine, can take weeks or months, a critical delay for patients with aggressive cancers. Another major challenge lies in the biology of the tumours themselves. Cancers are notoriously heterogeneous, meaning different cells within the same tumour can have different mutations, allowing some to escape the targeted immune response. Furthermore, many tumours create an 'immunosuppressive microenvironment' that actively hinders the immune cells the vaccine is trying to activate. This is why these vaccines are often tested in combination with 'checkpoint inhibitor' drugs like Keytruda, which help to take the brakes off the immune system so it can do its job more effectively.
The Path to Approval
Despite the impressive clinical trial results from companies like Moderna and Merck, no personalised mRNA cancer vaccine has yet received full regulatory approval for routine use. The process is slow and methodical. Companies must prove not only that the treatment works but that it is safe, and that they can manufacture it consistently and reliably for every single patient. Regulators require extensive data from largescale, controlled Phase 3 trials to be convinced. While Moderna is reportedly preparing to seek approval for its melanoma vaccine, the timeline remains uncertain. For newer companies like PopVax, the journey is just beginning. They will need to conduct their own extensive clinical trials to prove both safety and efficacy, a process that takes years and significant funding. While the initial steps of offering treatments via compassionate use can provide early data, it is no substitute for the rigorous evidence required for broad approval.
